Company news
Kala Bio, Inc. news in 2022
Kala Bio, Inc.'s news releases, calls and decks from 2022, newest first.
Kala Pharmaceuticals Announces FDA Acceptance of IND Application for KPI-012 for the Treatment of PCED
December 26, 2022
Kala Pharmaceuticals Announces Up to $31 Million Private Placement Financing
November 27, 2022
Kala Pharmaceuticals Announces Submission of Investigational New Drug Application for KPI-012 for the Treatment of Persistent Corneal Epithelial Defect
November 27, 2022
Kala Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Corporate Update
November 7, 2022
Kala Pharmaceuticals Announces Appointment of Marjan Farid, M.D., to its Board of Directors
October 31, 2022
Kala Pharmaceuticals Announces Reverse Stock Split
October 19, 2022
Kala Pharmaceuticals to Present at H.C. Wainwright 24th Annual Global Investment Conference
September 5, 2022
Kala Pharmaceuticals Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
August 18, 2022
Kala Pharmaceuticals Announces Distribution of Series D Preferred Stock to Holders of its Common Stock
August 17, 2022
Kala Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Corporate Update
August 10, 2022
Kala Pharmaceuticals to Report Second Quarter 2022 Financial Results and Host Conference Call
August 7, 2022
Kala Pharmaceuticals to Participate in Upcoming Investor Conferences in August
August 3, 2022
Kala Pharmaceuticals Completes Sale of EYSUVIS® and INVELTYS® to Alcon Inc
July 10, 2022
Kala Pharmaceuticals to Present at Jefferies Healthcare Conference
June 1, 2022
Kala Announces Entry into Definitive Agreement to Sell EYSUVIS® and INVELTYS® to Alcon Inc.
May 22, 2022
Kala Reports First Quarter 2022 Financial Results and Provides Corporate Update
May 15, 2022
Kala Pharmaceuticals to Report First Quarter 2022 Financial Results and Host Conference Call
May 8, 2022
Kala Pharmaceuticals Announces New Commercial and Medicare Coverage for EYSUVIS®
May 2, 2022
Kala Pharmaceuticals to Present Clinical Data for KPI-012, its Mesenchymal Stem Cell Secretome Product, for the Treatment of PCED at the 2022 ARVO Annual Meeting
April 30, 2022
Kala Pharmaceuticals to Present Phase 1b Clinical Data for KPI-012 in Patients with PCED at 2022 ARVO Annual Meeting
April 3, 2022
Kala Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update
March 28, 2022
Kala Pharmaceuticals to Report Fourth Quarter and Full Year 2021 Financial Results and Host Conference Call
March 22, 2022
Kala Pharmaceuticals Announces EYSUVIS® Now Covered on UnitedHealthcare Commercial and Cigna Medicare
March 7, 2022